Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> Amplification
These preclinical in vivo data provide a rationale for further clinical development of this combinatorial targeted therapy approach.
Authors
- Elisa de Stanchina (ORCID: https://orcid.org/0000-0002-3873-315X)
- Inna Khodos
- Zebing Liu (ORCID: https://orcid.org/0000-0003-4682-1253)
- Morana Vojnic (ORCID: https://orcid.org/0000-0001-5441-4119)
- Michael David Offin (ORCID: https://orcid.org/0000-0002-7959-3018)
- Igor Odintsov (ORCID: https://orcid.org/0000-0001-8073-8803)
- Romel Somwar
- Arielle Elkrief (ORCID: https://orcid.org/0000-0003-1981-1535)
- Marc Ladanyi (ORCID: https://orcid.org/0000-0001-9055-7213)
- Roger S. Smith (ORCID: https://orcid.org/0000-0002-6114-8258)
- Takuo Hayashi (ORCID: https://orcid.org/0000-0002-8544-9370)
- Charles M. Rudin (ORCID: https://orcid.org/0000-0001-5204-3465)
- Gregory J. Riely (ORCID: https://orcid.org/0000-0001-5357-4313)
- Allan J.W. Lui (ORCID: https://orcid.org/0000-0001-7624-3437)
- Vladimir Markov (ORCID: https://orcid.org/0000-0002-8190-3177)
- Jamie L. Bloom
Institutions
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/po.24.00241
- Citations
- 4
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Mesothelioma Applied Research Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Jazz Pharmaceuticals
- Kowa Company
- Mirati Therapeutics
- Genentech
- National Cancer Institute
- Daiichi Sankyo Europe